194 related articles for article (PubMed ID: 34334557)
1. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
J Toxicol Sci; 2021; 46(8):359-369. PubMed ID: 34334557
[TBL] [Abstract][Full Text] [Related]
2. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
3. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes].
Yanagida S; Kanda Y
Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
5. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
[TBL] [Abstract][Full Text] [Related]
6. Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.
Sakamoto K; Sakatoku K; Sugimoto S; Iwasaki N; Sano Y; Yamaguchi M; Kurokawa J
J Pharmacol Sci; 2019 Aug; 140(4):345-349. PubMed ID: 31521491
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Watanabe H; Honda Y; Deguchi J; Yamada T; Bando K
J Toxicol Sci; 2017; 42(4):519-527. PubMed ID: 28717111
[TBL] [Abstract][Full Text] [Related]
8. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Narkar A; Willard JM; Blinova K
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
[TBL] [Abstract][Full Text] [Related]
9. Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment.
Goßmann M; Linder P; Thomas U; Juhasz K; Lemme M; George M; Fertig N; Dragicevic E; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2020 Sep; 105():106892. PubMed ID: 32629160
[TBL] [Abstract][Full Text] [Related]
10. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives].
Yanagida S; Kawagishi H; Kanda Y
Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924
[TBL] [Abstract][Full Text] [Related]
11. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
12. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
[TBL] [Abstract][Full Text] [Related]
14. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
[TBL] [Abstract][Full Text] [Related]
15. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
16. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling.
Isobe T; Honda M; Komatsu R; Tabo M
J Toxicol Sci; 2019; 44(12):859-870. PubMed ID: 31813905
[TBL] [Abstract][Full Text] [Related]
18. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
20. Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes.
Okai Y; Matsune K; Yamanaka K; Matsui T; Pfeiffer Kaushik E; Harada K; Kohara H; Miyawaki A; Ozaki H; Wagoner M; Shinozawa T
J Pharmacol Toxicol Methods; 2020 Sep; 105():106893. PubMed ID: 32619502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]